Pharmacokinetics	pharmacokinetics	O	O	O	O
of	of	O	O	O	O
desipramine	desipramine	CHEMICALS	O	OTHERS	I
HCl	hcl	O	O	OTHERS	I
when	when	O	O	O	O
administered	administered	O	O	O	O
with	with	O	O	O	O
cinacalcet	cinacalcet	CHEMICALS	O	OTHERS	I
HCl	hcl	O	O	OTHERS	I
.	.	O	O	O	O

OBJECTIVE	objective	O	O	O	O
:	:	O	O	O	O
In	in	O	O	O	O
vitro	vitro	O	O	O	O
work	work	O	O	O	O
has	has	O	O	O	O
demonstrated	demonstrated	O	O	O	O
that	that	O	O	O	O
cinacalcet	cinacalcet	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
strong	strong	O	O	O	O
inhibitor	inhibitor	O	O	O	O
of	of	O	O	O	O
cytochrome	cytochrome	O	O	O	O
P450	p450	O	O	O	O
isoenzyme	isoenzyme	O	O	O	O
(	(	O	O	O	O
CYP	cyp	O	O	OTHERS	I
)	)	O	O	O	O
2D6	2d6	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
purpose	purpose	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
to	to	O	O	O	O
evaluate	evaluate	O	O	O	O
the	the	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
cinacalcet	cinacalcet	CHEMICALS	O	OTHERS	I
on	on	O	O	O	O
CYP2D6	cyp2d6	O	O	O	O
activity	activity	O	O	O	O
,	,	O	O	O	O
using	using	O	O	O	O
desipramine	desipramine	CHEMICALS	O	OTHERS	I
as	as	O	O	O	O
a	a	O	O	O	O
probe	probe	O	O	O	O
substrate	substrate	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
healthy	healthy	O	O	O	O
subjects	subjects	O	O	O	O
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
Seventeen	seventeen	O	O	O	O
subjects	subjects	O	O	O	O
who	who	O	O	O	O
were	were	O	O	O	O
genotyped	genotyped	O	O	O	O
as	as	O	O	O	O
CYP2D6	cyp2d6	O	O	O	O
extensive	extensive	O	O	O	O
metabolizers	metabolizers	O	O	O	O
were	were	O	O	O	O
enrolled	enrolled	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
randomized	randomized	O	O	O	O
,	,	O	O	O	O
open-label	open-label	O	O	O	O
,	,	O	O	O	O
crossover	crossover	O	O	O	O
study	study	O	O	O	O
to	to	O	O	O	O
receive	receive	O	O	O	O
a	a	O	O	O	O
single	single	O	O	O	O
oral	oral	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
desipramine	desipramine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
50	50	O	O	O	O
mg	mg	O	O	OTHERS	I
)	)	O	O	O	O
on	on	O	O	O	O
two	two	O	O	O	O
separate	separate	O	O	O	O
occasions	occasions	O	O	O	O
,	,	O	O	O	O
once	once	O	O	O	O
alone	alone	O	O	O	O
and	and	O	O	O	O
once	once	O	O	O	O
after	after	O	O	O	O
multiple	multiple	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
cinacalcet	cinacalcet	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
90	90	O	O	O	O
mg	mg	O	O	OTHERS	I
for	for	O	O	O	O
7	7	O	O	O	O
days	days	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Blood	blood	O	O	O	O
samples	samples	O	O	O	O
were	were	O	O	O	O
obtained	obtained	O	O	O	O
predose	predose	O	O	O	O
and	and	O	O	O	O
up	up	O	O	O	O
to	to	O	O	O	O
72	72	O	O	O	O
h	h	CHEMICALS	O	OTHERS	I
postdose	postdose	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Fourteen	fourteen	O	O	O	O
subjects	subjects	O	O	O	O
completed	completed	O	O	O	O
both	both	O	O	O	O
treatment	treatment	O	O	O	O
arms	arms	O	O	O	O
.	.	O	O	O	O

Relative	relative	O	O	O	O
to	to	O	O	O	O
desipramine	desipramine	CHEMICALS	O	OTHERS	I
alone	alone	O	O	O	O
,	,	O	O	O	O
mean	mean	O	O	O	O
AUC	auc	O	O	O	O
and	and	O	O	O	O
C(max	c(max	O	O	O	O
)	)	O	O	O	O
of	of	O	O	O	O
desipramine	desipramine	CHEMICALS	O	OTHERS	I
increased	increased	O	O	O	O
3.6-	3.6-	O	O	O	O
and	and	O	O	O	O
1.8-fold	1.8-fold	O	O	O	O
when	when	O	O	O	O
coadministered	coadministered	O	O	O	O
with	with	O	O	O	O
cinacalcet	cinacalcet	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
t	t	O	O	O	O
(	(	O	O	O	O
1/2,z	1/2,z	O	O	O	O
)	)	O	O	O	O
of	of	O	O	O	O
desipramine	desipramine	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
longer	longer	O	O	O	O
when	when	O	O	O	O
desipramine	desipramine	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
coadministered	coadministered	O	O	O	O
with	with	O	O	O	O
cinacalcet	cinacalcet	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
21.0	21.0	O	O	O	O
versus	versus	O	O	O	O
43.3	43.3	O	O	O	O
hs	hs	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
t	t	O	O	O	O
(	(	O	O	O	O
max	max	O	O	O	O
)	)	O	O	O	O
was	was	O	O	O	O
similar	similar	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
regimens	regimens	O	O	O	O
.	.	O	O	O	O

Fewer	fewer	O	O	O	O
subjects	subjects	O	O	O	O
reported	reported	O	O	O	O
adverse	adverse	O	O	O	O
events	events	O	O	O	O
following	following	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
desipramine	desipramine	CHEMICALS	O	OTHERS	I
alone	alone	O	O	O	O
than	than	O	O	O	O
when	when	O	O	O	O
receiving	receiving	O	O	O	O
desipramine	desipramine	CHEMICALS	O	OTHERS	I
with	with	O	O	O	O
cinacalcet	cinacalcet	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
33	33	O	O	O	O
versus	versus	O	O	O	O
86	86	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
most	most	O	O	O	O
frequent	frequent	O	O	O	O
of	of	O	O	O	O
which	which	O	O	O	O
(	(	O	O	O	O
nausea	nausea	O	DISEASE	OTHERS	I
and	and	O	O	O	O
headache	headache	O	DISEASE	OTHERS	I
)	)	O	O	O	O
have	have	O	O	O	O
been	been	O	O	O	O
reported	reported	O	O	O	O
for	for	O	O	O	O
patients	patients	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
either	either	O	O	O	O
desipramine	desipramine	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
cinacalcet	cinacalcet	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
This	this	O	O	O	O
study	study	O	O	O	O
demonstrates	demonstrates	O	O	O	O
that	that	O	O	O	O
cinacalcet	cinacalcet	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
strong	strong	O	O	O	O
inhibitor	inhibitor	O	O	O	O
of	of	O	O	O	O
CYP2D6	cyp2d6	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
data	data	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
during	during	O	O	O	O
concomitant	concomitant	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
cinacalcet	cinacalcet	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
dose	dose	O	O	O	O
adjustment	adjustment	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
necessary	necessary	O	O	O	O
for	for	O	O	O	O
drugs	drugs	O	O	O	O
that	that	O	O	O	O
demonstrate	demonstrate	O	O	O	O
a	a	O	O	O	O
narrow	narrow	O	O	O	O
therapeutic	therapeutic	O	O	O	O
index	index	O	O	O	O
and	and	O	O	O	O
are	are	O	O	O	O
metabolized	metabolized	O	O	O	O
by	by	O	O	O	O
CYP2D6	cyp2d6	O	O	O	O
.	.	O	O	O	O

